RYTM - Rhythm acquires rights to Phase 2 anti-obesity drug from LG Chem
2024-01-04 09:51:10 ET
More on Rhythm Pharmaceuticals
- Rhythm Pharmaceuticals: Major Catalysts Due For Weight Loss Specialist
- Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2023 Earnings Call Transcript
- Rhythm Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call Presentation
- Pfizer hits new 52-week low after weight loss setback
- Rhythm Pharmaceuticals Q3 2023 Earnings Preview
For further details see:
Rhythm acquires rights to Phase 2 anti-obesity drug from LG Chem